Delaware Chapter of the American College of Cardiology

Join us for the ACC Delaware Chapter Meeting: ACC by the Sea for engaging live education sessions from local, regional, and national experts with Q&A real-time. The educational meeting includes topics of cardio obstetrics, lipids, amyloid, etc., and a chapter update from our Governor Dr. Vinay Hosmane. Participation in this event will earn CME/CNE/and MOC. We look forward to seeing you (IN-PERSON) September 12 - 13, 2025!

For more Information and Register: Delaware ACC By the Sea: 2025 Chapter Meeting

Delaware Chapter of the American College of Cardiology

Our purpose is to contribute to the prevention of cardiovascular diseases, to ensure optimal quality of care for individuals with such diseases, and to foster the highest professional ethical standards. Please let us know what information you want to see here. Feel free to contact us with your ideas, needs and comments.

ACC Live Courses

For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

Latest in Cardiology from ACC.org

New Studies Add to Evidence Involving Optimal Treatment of Patients Post-Ischemic Stroke
Treatment of patients following ischemic stroke was the focus of three separate studies published in JAMA, two of which involved use of intravenous tenecteplase and the other involving thrombectomy plus intra-arterial alteplase.
No Child Left Behind: The Case For Early Lipid Screening
Atherosclerotic cardiovascular disease (ASCVD) is traditionally recognized as a disease of midadulthood. However, atherogenesis begins in childhood. Subclinical atherosclerosis can be detected as early as 8-10 years of age.
JACC Spotlight Issue Provides Expert Insight on 2026 Dyslipidemia Guideline
A special JACC Spotlight Issue supporting the recently published 2026 ACC/AHA Guideline on the Management of Dyslipidemia, offers commentaries that provide a comprehensive overview of the new guideline recommendations and expert insights into understanding the science behind the recommendations...
FDA Update: Agency Approves Baxdrostat to Treat Adults With HTN
The U.S. Food and Drug Administration (FDA) has approved baxdrostat, a first-in-class oral aldosterone synthase inhibitor, as an add-on therapy for hypertension in adults whose blood pressure (BP) is not adequately controlled with other antihypertensive medications.
SURMOUNT-MAINTAIN: Continuing Tirzepatide Maintains Weight Loss
In patients with obesity, continuing tirzepatide at either the maximum tolerated dose (MTD) of 10 or 15 mg or a reduced dose of 5 mg was safe and effectively maintained weight loss along with its associated health benefits, compared to switching to placebo, according to results from the SURMOUNT-MAINTAIN trial published May 12 in The […]